A study found that many breast cancer immunotherapy trials have yielded modest clinical impact, and 25% failed to report outcomes.
Breast cancer immunotherapy trials yield modest clinical impact, with a quarter of trials failing to report their outcomes, particularly among single-center studies which are more likely to go unreported, and many phase 2 studies failing to translate into successful phase 3 trials.
In this cross-sectional study, researchers evaluated 331 immunotherapy trials, initiated between January 2004 and April 2023 that enrolled 48,844 patients with breast cancer.A trial was considered reported if the results were posted on ClinicalTrial.gov or reported as an abstract or a manuscript. Overall, 120 trials met their completion date up to November 2022; of these, 30 failed to report outcomes, which included two phase 3 trials.Phase 1 trials had the highest rate of nonreporting , followed by phase 2 and phase 3 trials."The findings of this study suggest that the large number of immunotherapy trials being run have yielded modest clinical impact," the authors wrote.
Malignant Breast Neoplasm Breast Carcinoma Biologic Therapy Biologics Immunotherapy Breast Mammary Gland Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Grant Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Biomarker Biological Marker Multi-Biomarker Disease Activity MBDA
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
NZD/USD trims a part of modest intraday gains after softer NZ inflation expectations dataThe NZD/USD pair attracts some dip-buying following the previous day's modest pullback from a two-and-half-week high and retakes the 0.6000 psychological mark during the Asian session on Thursday.
Read more »
USD/CHF sticks to intraday gains amid recovery in risk sentiment, modest USD strengthThe USD/CHF pair attracts some buyers near the 0.8500 psychological mark on Tuesday and builds on the overnight goodish rebound from its lowest level since early January.
Read more »
WTI trades with modest intraday gains above mid-$73.00s, lacks bullish convictionWest Texas Intermediate (WTI) US crude Oil prices edge higher during the Asian session on Tuesday and recover further from a multi-month low, around the $71.20-$71.15 region touched the previous day.
Read more »
USD/CAD sticks to modest gains above 1.3800 mark, lacks bullish convictionThe USD/CAD pair attracts some dip-buyers on Thursday and moves away from a one-week trough, around the 1.3785 region touched the previous day.
Read more »
Indian Rupee posts modest gains, focus on Fed rate decisionThe Indian Rupee (INR) trades stronger on Tuesday despite the recovery of the US Dollar (USD).
Read more »
WTI sticks to modest intraday gains amid Middle East tensions, remains below $77.00 markWest Texas Intermediate (WTI) US crude Oil prices kick off the new week on a positive note and reverse a part of Friday's heavy losses back closer to the lowest level since June 10, around the $75.75 region touched the previous day.
Read more »